Policy & Regulation
Basilea Pharmaceutica enters exclusive license agreement with Venatorx Pharmaceuticals
15 August 2025 - Basilea Pharmaceutica Ltd, (SIX:BSLN), a Switzerland-based commercial-stage biopharmaceutical company, announced on Thursday that it has entered into an exclusive license agreement wi...
Nanoscope Therapeutics announces positive results from STARLIGHT clinical trial
15 August 2025 - Nanoscope Therapeutics Inc., a Texas-based biotechnology company involved in developing and commercialising novel gene-agnostic therapies for patients suffering vision loss from retin...
Leads Biolabs completes patient enrollment in pivotal Opamtistomig trial for EP-NEC
14 August 2025 - Nanjing Leads Biolabs Co, Ltd (9887.HK) announced on Thursday that it has completed patient enrollment in its pivotal single-arm registrational trial (CTR20213023) evaluating Opamtist...
Remegen's Telitacicept meets Sjogren's syndrome Phase III trial's primary endpoint
14 August 2025 - Remegen (688331.SH/09995.HK), a China-based pharmaceutical company, announced on Wednesday that its global first-in-class BLyS (BAFF)/APRIL dual-target fusion protein drug, Telitacice...
Phosphorex appoints chief executive officer
14 August 2025 - Phosphorex, a US-based, drug delivery-focused contract development and manufacturing organisation (CDMO) and Ampersand Capital Partners portfolio company announced on Wednesday the ap...
CuraCell secures German regulatory clearance for clinical trial of CC-38 TIL therapy
13 August 2025 - Sweden-based clinical-stage immunotherapy company CuraCell Holding AB announced on Wednesday that it has received approval from the Paul-Ehrlich-Institut to begin a Phase I/IIa clinic...